Safety and effectiveness of direct-acting antivirals in patients with chronic hepatitis C and chronic kidney disease

Ji Eun Ryu, Myeong Jun Song, Seok-Hwan Kim, Jung Hyun Kwon, Sun Hong Yoo, Soon Woo Nam, Hee Chul Nam, Hee Yeon Kim, Chang Wook Kim, Hyun Yang, Si Hyun Bae, Do Seon Song, U Im Chang, Jin Mo Yang, Sung Won Lee, Hae Lim Lee, Soon Kyu Lee, Pil Soo Sung, Jeong Won Jang, Jong Young Choi, and Seung Kew Yoon

Division of Hepatology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea

Safety and effectiveness of direct-acting antivirals in patients with chronic hepatitis C and chronic kidney disease

Patients

Treatment

Result

Efficacy

Per protocol

Safety

Tolerable

Did not affect deterioration of renal function

362 CKD patients with HCV infection

Direct-acting antibody (DAA)

Glecaprevir/pibrentasvir
Sofosbuvir/ribavirin
Ledipasvir/sofosbuvir
Daclatasvir/asunaprevir

Efficacy

Conclusion

DAAs shows comparable SVR12 and safety in CKD patients (stage 3, 4 and 5) with HCV compared with patients with stage 1 and 2. The effectiveness and safety of DAAs may be related to the treatment duration.

Received: October 26, 2021
Revised: December 11, 2021
Accepted: January 17, 2022

Correspondence to Myeong Jun Song, M.D.
Division of Hepatology, Department of Internal Medicine, Daejeon St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, 64 Daheung-ro, Jung-gu, Daejeon 34943, Korea
Tel: +82-42-220-9305, Fax: +82-42-220-9565, E-mail: mjsong95@gmail.com
https://orcid.org/0000-0001-5244-0372

Copyright © 2022 The Korean Association of Internal Medicine
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
INTRODUCTION

Chronic hepatitis C virus (HCV) infection is a major cause of liver diseases such as liver cirrhosis and hepatocellular carcinoma. The goal of treatment of HCV is to achieve a sustained virologic response (SVR) and eradicate the virus. In the interferon era, treatment of HCV infection is hampered by poor tolerability and a low SVR rate [1-3]. Interferon-based treatment has an SVR of up to 50% and a high incidence of adverse events (AEs) [4]. HCV treatment has shifted from pegylated interferon-based therapy to direct acting antivirals (DAAs), which have high SVR rates, less toxicity, and good tolerability [5]. DAAs have been used successfully in patients with difficult-to-treat HCV infection, including those with treatment failure, and decompensated cirrhosis, as well as those who have undergone organ transplantation [6,7].

Early detection and treatment of HCV associated with kidney disease is paramount to prevent the progressive loss of kidney function. HCV-infected patients have a 23% greater risk of chronic kidney disease (CKD) compared to uninfected patients [8]. Chronic HCV infection is associated with an increased risk of end-stage renal disease (ESRD) [9]. Therefore, the Kidney Disease Improving Global Outcomes (KDIGO) guidelines suggest screening patients with chronic HCV for creatinine clearance and proteinuria [10]. The duration of chronic HCV infection influences the risk of CKD progression. HCV seroconversion within 12 months is not a major risk factor for CKD, but cirrhosis and other comorbidities contribute to the significantly increased prevalence of CKD among patients with chronic HCV infection [11]. In addition, chronic HCV infection worsens outcomes in patients at every stage of CKD. Moreover, HCV infection accelerates the decline in renal function and increases the mortality rate of patients with CKD stage 4 or 5 [12,13]. Patients on dialysis for ESRD are particularly vulnerable to HCV infection [14]. The estimated prevalence of chronic HCV infection in hemodialysis centers is 4% to 50% [15,16]. Therefore, treatment strategies for difficult-to-treat HCV-infected patients with CKD are necessary to improve renal and liver-related morbidity and mortality.

DAAs are reportedly safe and effective in patients with CKD. The first DAA regimen approved in Korea was a 24-week course of daclatasvir (DCV) and asunaprevir (ASV) in 2015 [17,18]. However, there are few data on the effectiveness and safety of DAAs for patients with CKD (particularly those with severe renal impairment [estimated glomerular filtration rate, eGFR < 30 mL/min/1.73 m<sup>2</sup>]) in clinical practice. DAAs have a low rate of AEs, although there is concern over drug-drug interactions (DDIs) with DAAs in patients with underlying comorbidities [19]. Therefore, we evaluated
the effectiveness and safety of DAAs in HCV patients with CKD in Korea.

METHODS

In this retrospective, multicenter study based on prospectively collected demographic, clinical and biochemical data, 362 patients were enrolled from February 2015 to December 2019, i.e., beginning immediately after the introduction of DAAs in Korea. The patients were treated using the regimens covered by National Health Insurance. Subjects who met the following inclusion criteria were enrolled: adult males and non-pregnant females, aged ≥ 18 years; documented evidence of chronic HCV infection (e.g., HCV RNA for > 6 months); and chronic hepatitis or liver cirrhosis. Liver cirrhosis was assessed by radiological imaging (ultrasonography or liver dynamic computed tomography at screening showing coarse liver echotexture with nodularity and a small liver or the features of portal hypertension (HTN) such as splenomegaly or varices). The patients’ Child-Pugh class was A or B. Regarding HCV treatment history, HCV treatment-naïve participants were defined as those who had never received HCV treatment with an approved or investigational drug. HCV treatment-experienced participants were those who had previously received pegylated interferon-based regimen (with or without ribavirin [RBV] and not including DAAs) for HCV treatment.

The exclusion criteria were as follows: decompensated episodes including refractory ascites or hepatic encephalopathy; evidence of a medical condition contributing to chronic liver disease other than HCV or seropositivity for human immunodeficiency virus or hepatitis B virus; diagnosed or suspected hepatocellular carcinoma or other malignancies; significant cardiovascular, pulmonary, or neurological disease and uncontrolled diabetes or HTN; and current alcohol or substance abuse.

Patient records were de-identified and their data were anonymized. This study was conducted in accordance with the Declaration of Helsinki, and approval was obtained from the Ethics Review Board of the Catholic University of Korea (XC20RIDI0186). Written informed consent by the patients was waived due to a retrospective nature of this study.

Treatment protocol

Glecaprevir/Pibrentasvir
For the glecaprevir/pibrentasvir (G/P) regimen, patients received glecaprevir 300 mg and pibrentasvir 120 mg daily for 8 weeks for chronic hepatitis, or for 12 weeks for liver cirrhosis or in case of prior treatment failure. No dose modification was applied according to renal function.

Sofosbuvir/Ledipasvir
In genotype 1 HCV patients, sofosbuvir/ledipasvir (SOF/LDV; 400 mg/90 mg) daily for 12 weeks was prescribed for chronic hepatitis. In treatment-experienced cirrhotic patients, SOF/LDV for 24 weeks or SOF/LDV with RBV for 12 weeks was prescribed. SOF was not used in patients with an eGFR < 30 mL/min/1.73 m².

SOF and RBV
For genotype 2 HCV patients, the combination of SOF (400 mg) and RBV for 12 weeks was prescribed. For cirrhotic patients, SOR and RBV for 16 weeks was prescribed. The RBV dose was determined according to body weight (< 65 kg: 1,000 mg; ≥ 65 kg: 1,200 mg). SOF was not used in patients with an eGFR < 30 mL/min/1.73 m².

DCV and ASV
For genotype 1b HCV patients, the combination of DCV and ASV for 24 weeks was prescribed if NS5A resistance associated variants (RAV), including L31F/I/M/V and Y93H, were absent. In cases of severe renal impairment, the ASV dose was reduced to 100 mg daily. This was the first interferon-free DAA regimen approved in South Korea (in 2015), and it was the only regimen available for patients with CKD (particularly those with severe renal impairment) until approval of the G/P regimen in South Korea in 2018.

Definition and classification of CKD and severe renal impairment
The eGFR was calculated using the Modification of Diet in Renal Disease study equation: GFR (mL/min/1.73 m²) = 175 × (Scr)-1.154 × (age)^0.203 × (0.742 if female) × (1.212 if African American); where: Scr is the serum creatinine level in mg/dL. All the patients in this study were Korean.

CKD was classified according to KDIGO Clinical Practice Guidelines for CKD based on the eGFR for ≥ 3–6 months. The eGFR was assessed at 3–6 months before and at the
time of treatment. Only patients with an eGFR < 60 mL/min/1.73 m² for all measurements were considered to have CKD. This definition follows the recommendations of the CKD guidelines. The CKD stage was classified according to the eGFR as follows: stage 1, eGFR ≥ 90 mL/min/1.73 m²; stage 2–4, 15 to 90 mL/min/1.73 m²; and stage 5, eGFR < 15 mL/min/1.73 m² or dialysis. The definition of severe renal impairment was an eGFR < 30 mL/min/1.73 m² (i.e., CKD stage 4–5).

Endpoints and laboratory evaluations
The primary endpoints were sustained virologic response at week 12 after treatment (SVR12) after treatment, and safety. SVR12 was defined as an HCV RNA level less than the lower limit of quantification (15 IU/mL). Safety, i.e., AEs (anemia, skin rash, and discontinuation of study medication), was also evaluated.

The secondary endpoints were virological response to treatment at week 4 and end of treatment (EOT); normalized alanine transferase (ALT); and treatment failure including virological breakthrough and relapse. Any patient who met one of the following criteria was considered to have had on-treatment virologic failure and was required to discontinue treatment: an increase in the HCV RNA level of > 10² IU/mL after achieving undetectable HCV RNA, or a confirmed increase in the HCV RNA of > 1 log₁₀ from the nadir during the treatment period.

Treatment regimens were determined by baseline characteristics including CKD stage, liver cirrhosis, and genotype, and physicians’ selection of available regimen approved by medical insurance during the study period. All patients were followed-up every 4 weeks, EOT and after the treatment period. Physical examinations, including tolerability assessment and laboratory tests were performed at baseline and 4-week intervals thereafter.

Statistical analysis
Continuous variables are presented as medians and ranges, and categorical variables as numbers and percentages. The Friedman test was used to evaluate changes in the eGFR level over time. To compare groups with respect to treatment responses and AEs, Fisher’s exact test was used. Data are medians and ranges or means ± standard deviations. The primary endpoint was evaluated by conducting per-protocol and modified intention-to-treat (ITT) analyses. The per-protocol analysis was computed as SVR12 for patients who completed treatment per the schedule. The modified ITT analysis was conducted under the assumption that all treatment interruptions were protocol failures in all patients treated with at least one dose of DAAs. A multivariate logistic regression analysis was performed using variables with a p < 0.05 in the univariate analyses to evaluate factors predictive of SVR12. Statistical analyses were performed using SPSS software version 18.0 (SPSS Inc., Chicago, IL, USA).

RESULTS

Baseline characteristics
Among 362 patients, 307 completed DAA treatment, of whom 291 patients were followed after EOT, and 16 were excluded due to follow-up loss (Fig. 1). The subjects comprised 87 patients (62 with CKD stage 3 and 25 with CKD stage 4–5), of whom 22 were undergoing hemodialysis. The baseline characteristics of the enrolled patients are listed in Table 1. Most patients were infected with genotype 1b HCV (67.7%). The median age of the patients was 61 years, and 36.1% (n = 111) were male. Eighty-four patients had liver cirrhosis (27.3%); the others had chronic hepatitis. HCV patients with CKD stage (eGFR < 60 mL/min/1.73 m²) had significantly higher rates of diabetes mellitus (DM) and HTN than patients with an eGFR ≥ 60 mL/min/1.73 m² (34.4% vs. 17.2%, 64.3% vs. 28.6%, p = 0.005 and p = 0.000, respectively). Major causes of CKD were also DM and HTN. Forty-seven patients (15.3%) had previously received pegylated IFN-based or DAA therapy; the others were treatment-naïve. Patients with CKD stage 1–2 received G/P...
and SOF/LDV (40.9% and 59.1%, respectively). Patients with CKD stage 3 were administrated SOF-based regimens (67.7%), DCV + ASV (22.5%) and G/P (9.6%). Patients with CKD stage 4–5 received G/P (60%) and DCV + ASV (40%) regimens.

### Treatment effectiveness

During follow-up, the overall SVR12 rate was 94.7% (291/307) in the per protocol analysis. HCV patients with CKD stage 1 and 2 (eGFR ≥ 60 mL/min/1.73 m²) showed an SVR12 rate of 97.2% and 95.4%, respectively. The SVR12 rate of CKD stage 3 and 4–5 (eGFR < 60 mL/min/1.73 m²) patients was 91.9% and 91.6%, respectively. Also, 90.9% of patients undergoing hemodialysis achieved SVR12 (Fig. 2A).

The modified ITT analysis yielded SVR12 rates in patients with CKD stage 3 and 4–5 (83.8% and 78.5%, respectively) comparable with those in patients with CKD stage 1 and 2, (82.3% and 79.4%, respectively) (Fig. 2B). Although HCV patients with CKD stage 4 showed a low SVR12, the SVR12 rate did not differ significantly according to CKD stage (p = 0.094).

Subgroup analyses showed no effect of age, gender, DM, HTN, cirrhosis, genotype, HCV RNA level (> 10⁶ IU/mL), treatment experience, or treatment regimen on the SVR12 rate (p = 0.139, p = 0.076, p = 0.492, p = 0.248, p = 0.578, p = 0.227, p = 0.126, p = 0.545, or p = 0.073, respectively) (Fig. 3). In HCV patients with severe renal impairment, the SVR12 rate did not differ according to any of these factors, including treatment regimen (G/P vs. DCV + ASV).

### Table 1. Baseline characteristics of the patients (n = 307)

| Variable                  | CKD stage 1 (n = 109) | CKD stage 2 (n = 111) | CKD stage 3 (n = 62) | CKD stage 4 (n = 3) | CKD stage 5 (n = 22) | p value |
|---------------------------|-----------------------|-----------------------|----------------------|---------------------|---------------------|---------|
| Age, yr                   | 55 ± 11               | 62 ± 12               | 69 ± 10              | 60 ± 4              | 56 ± 12             | 0.000   |
| Male sex                  | 42 (39)               | 36 (32)               | 20 (32)              | 2 (67)              | 11 (50)             | 0.357   |
| Diabetes                  | 18 (17)               | 20 (18)               | 20 (32)              | 0                   | 10 (45)             | 0.005   |
| Hypertension              | 18 (17)               | 45 (41)               | 42 (68)              | 1 (33)              | 13 (59)             | 0.000   |
| History of prior treatment| 15 (14)               | 14 (13)               | 17 (27)              | 0                   | 1 (0.04)            | 0.035   |
| Hb, g/dL                  | 13.7 ± 1.7            | 13.4 ± 1.3            | 11.9 ± 1.7           | 10.9 ± 2.7          | 11.4 ± 1.1          | 0.000   |
| Platelets, × 10⁹/mm³      | 189 ± 98              | 177 ± 66              | 151 ± 63             | 144 ± 89            | 156 ± 63            | 0.047   |
| Serum creatinine, mg/dL   | 0.65 ± 0.12           | 0.85 ± 0.14           | 1.25 ± 0.24          | 2.59 ± 0.58         | 7.94 ± 2.04         | 0.000   |
| eGFR, mL/min/1.73 m²      | 109 ± 17              | 76 ± 8                | 48 ± 7               | 24 ± 3              | 7 ± 2               | 0.000   |
| AST, IU/L                 | 67 ± 50               | 53 ± 40               | 69 ± 64              | 33 ± 10             | 29 ± 17             | 0.003   |
| ALT, IU/L                 | 69 ± 72               | 54 ± 51               | 62 ± 55              | 21 ± 6              | 27 ± 23             | 0.022   |
| Albumin, g/dL             | 4.1 ± 0.4             | 4.1 ± 0.4             | 3.8 ± 0.4            | 3.3 ± 0.3           | 4.1 ± 0.5           | 0.5      |
| Total bilirubin, mg/dL    | 0.9 ± 1.1             | 0.8 ± 0.3             | 0.8 ± 0.4            | 0.5 ± 0.0           | 0.5 ± 0.2           | 0.287   |
| Liver cirrhosis           | 27 (24.7)             | 25 (22.5)             | 22 (35.4)            | 0                   | 10 (45.4)           | 0.352   |
| Child A/B                 | 105/4                 | 108/3                 | 58/4                 | 3/0                 | 22/0                | 0.779   |
| AFP, ng/mL                | 7.5 ± 11.7            | 8.9 ± 22.6            | 15.0 ± 27.3          | 4.6 ± 1.2           | 4.0 ± 4.9           | 0.148   |
| Genotype 1/2              | 79/30                 | 80/31                 | 35/27                | 2/1                 | 12/10               | 0.114   |
| HCV RNA, log IU/mL        | 5.7 ± 0.95            | 5.6 ± 1.05            | 5.6 ± 1.08           | 5.1 ± 1.73          | 5.2 ± 1.29          | 0.619   |

Values are presented as mean ± standard deviation or number (%).

CKD, chronic kidney disease; Hb, hemoglobin; eGFR, estimated glomerular filtration rate; AST, aspartate transaminase; ALT, alanine transaminase; AFP, alpha-fetoprotein; HCV, hepatitis C virus; G/P, glecaprevir/pibrentasvir; SOF/LDV, sofosbuvir/ledipasvir; DCV, daclatasvir; ASV, asunaprevir.
Eighty-seven patients with CKD completed DAAs therapy and 79 patients had an SVR at 12 weeks. Six patients discontinued treatment for administrative reasons (nonadherence due to AEs, n = 5; loss to follow-up, n = 1). Two patients (CKD stage 3 and 5, respectively) showed treatment failure. All patients received DCV and ASV. One patient (stage 3) showed viral breakthrough at EOT. The other patient (stage 5) showed viral relapse after 12 weeks of treatment. The rates of treatment failure and cessation of DAAs were 1.6% (1/62) and 7.2% (4/56) in stage 1 and 2, 2.8% (3/109) and 0% in stage 1 and 2.7% (3/111), and 1.8% (2/111) in stage 2.

### Safety and tolerability

In total, 307 patients (84.8%) completed DAA treatment. The majority of AEs was of mild or moderate severity; the most common (> 2%) were dizziness, and gastrointestinal side effects (nausea, vomiting, and anemia).

There was one episode of elevated ALT in one patient with CKD stage 2 during the treatment period. Anemia occurred in nine patients (2.9%), possibly due to RBV-induced AEs or underlying renal disease (Table 2). Four patients with CKD stage 3 discontinued DAAs due to AEs (6.4%). The AEs related to treatment discontinuation were dizziness, and gastrointestinal side effects (nausea, vomiting, and anemia). The regimens of these patients were G/P (n = 1), the

---

**Figure 2.** The virological response at week 4 (rapid virological response [RVR]), end of treatment and after 12 weeks of treatment with direct acting antivirals according to chronic kidney stage. (A) Per-protocol, (B) modified intention-to-treat (ITT). HCV, hepatitis C virus; LLQQ, lower limit of quantification; EOT, end of treatment; SVR12, sustained virologic response at week 12 after treatment.

**Figure 3.** Sustained virologic response at week 12 after treatment (SVR12) according to subgroup. HCV, hepatitis C virus; LLQQ, lower limit of quantification; DM, diabetes mellitus; HTN, hypertension.
SOF-based regimen (n = 2), and DCV + ASV (n = 1). Two patients with CKD stage 4 and 5 discontinued treatments due to symptom-related nonadherence (8%); they were treated with G/P and DCV + ASV, respectively.

Side effect of the G/P regimen comprised nausea or vomiting, fatigue, and dizziness (1.8%, 0.9%, and 0.9%, respectively). Anemia was the most frequent (6.2%) side effect of SOF-based regimens containing RBV, followed by dizziness (4.0%), fatigue (2.9%), nausea (1.7%). DCV + ASV also caused gastrointestinal symptoms, including nausea or vomiting (4.1%).

Kidney function deterioration is a concern when using DAAs, although clinical trials showed a comparable safety profile. In our cohort, the eGFR and serum creatinine levels were generally stable during treatment. The progression of CKD stage from baseline to week 12 after treatment is de-

Table 2. Treatment failure, adverse events and laboratory abnormalities depending on CKD stage

| Adverse events                | CKD stage 1 (n = 109) | CKD stage 2 (n = 111) | CKD stage 3 (n = 62) | CKD stage 4 (n = 3) | CKD stage 5 (n = 22) | Total (n = 307) |
|------------------------------|-----------------------|-----------------------|----------------------|---------------------|----------------------|-----------------|
| Symptomatic events           |                       |                       |                      |                     |                      |                 |
| Fatigue/weakness             | 1 (0.9)               | 2 (1.8)               | 3 (4.8)              | 0                   | 0                    | 6 (1.9)         |
| Headache                     | 1 (0.9)               | 0                     | 0                    | 0                   | 0                    | 1 (0.3)         |
| Dizziness                    | 1 (0.9)               | 2 (1.8)               | 5 (8.0)              | 0                   | 0                    | 8 (2.6)         |
| Nausea/vomiting              | 0                     | 1 (0.9)               | 4 (6.4)              | 0                   | 2 (9.0)              | 7 (2.2)         |
| Weight loss                  | 1 (0.9)               | 0                     | 0                    | 0                   | 1 (0.3)              |                 |
| Insomnia                     | 1 (0.9)               | 0                     | 0                    | 0                   | 1 (0.3)              |                 |
| Palpitation                  | 0                     | 1 (0.9)               | 1 (1.6)              | 0                   | 0                    | 2 (0.6)         |
| Bradycardia                  | 0                     | 0                     | 0                    | 0                   | 1 (4.5)              | 1 (0.3)         |
| Pruritus                     | 0                     | 0                     | 1 (1.6)              | 0                   | 0                    | 1 (0.3)         |
| Tinnitus                     | 0                     | 0                     | 1 (1.6)              | 0                   | 0                    | 1 (0.3)         |
| Laboratory abnormalities     |                       |                       |                      |                     |                      |                 |
| AST or ALT elevation         | 0                     | 1 (0.9)               | 0                    | 0                   | 0                    | 1 (0.3)         |
| Anemia                       | 1 (0.9)               | 1 (0.9)               | 7 (11.2)             | 0                   | 0                    | 9 (2.9)         |
| Discontinuation              |                       |                       |                      |                     |                      |                 |
| Symptomatic events           | 0                     | 2 (1.8)               | 4 (6.4)              | 0                   | 1 (4.5)              | 8 (2.4)         |
| Breakthrough                 | 3 (2.8)               | 3 (2.7)               | 1 (1.6)              | 0                   | 1 (4.5)              | 8 (2.4)         |
| Laboratory events            | 0                     | 0                     | 0                    | 0                   | 1 (4.5)              | 1 (0.3)         |
| Nonmedical cause             | 0                     | 0                     | 1 (33.3)             | 0                   | 1 (0.3)              |                 |

Values are presented as number (%).
CKD, chronic kidney disease; AST, aspartate transaminase; ALT, alanine transferase.

Table 3. Progression of CKD stage from baseline to last visit

| Baseline CKD stage | CKD stage after 12 weeks after treatment |
|--------------------|------------------------------------------|
|                    | Stage 1 | Stage 2 | Stage 3 | Stage 4 | Stage 5 |
| Stage 1            | 82 (75.2) | 24 (22.0) | 3 (2.7) | 0 | 0 |
| Stage 2            | 17 (15.3) | 87 (78.3) | 7 (6.3) | 0 | 0 |
| Stage 3            | 0 | 10 (18.1) | 43 (78.1) | 2 (3.6) | 0 |
| Stage 4            | 0 | 0 | 0 | 2 (100) | 0 |
| Stage 5            | 0 | 0 | 0 | 0 | 22 (100) |

Values are presented as number (%).
CKD, chronic kidney disease.
tained in Table 3. Although most patients remained at the same CKD stage, 10 (9%) with CKD stage 1–2 progressed to stage 3, although there was no significant difference in CKD progression according to CKD stage ($p = 0.522$).

**DISCUSSION**

Chronic HCV-infected patients with renal impairment are a special population for HCV treatment. Although current guidelines recommend various first-line DAA therapies such as elbasvir/grazoprevir, G/P, there are several medical issues (e.g., comorbidity of advanced liver disease) and other therapies may not be available under contemporary National Health Insurance coverage in South Korea [20]. Therefore, we evaluated the effectiveness and safety of DAAs available for patients with renal impairment in South Korea.

In our cohort, 307 patients received four DAA regimens (G/P, SOF/RBV, LDV/SOF, and DCV/ASV). The pooled SVR12 rate in patients with renal impairment was satisfactory (91.8%). Patients on hemodialysis had an SVR12 rate of 90.9%. The small number of patients with renal impairment might explain the lower SVR12 compared with those without renal impairment.

G/P is an effective option for HCV patients with severe renal impairment. Glecaprevir, a nonstructural viral protein 3/4A protease inhibitor, combined with pibrentasvir, a nonstructural viral protein 5A inhibitor, is a potent DAA regimen approved for all HCV genotypes [21]. Metabolism and clearance of G/P occur primarily within the biliary system with negligible kidney excretion, so G/P is suitable for patients with kidney disease including those on dialysis for whom dosage adjustment is not required [22]. G/P showed a comparable SVR12 rate (90.4%) in patients with renal impairment (eGFR < 60 mL/min/1.73 m²). G/P is reportedly effective in treating patients with renal impairment and HCV infection (SVR12 > 98%) [23-25]. Especially, in patients with CKD stage 4 or 5, the SVR12 rates in the G/P group were 100% and 92.8%, respectively. Our results are consistent with previous study in Taiwan that reported SVR12 rates of 100% and 98.7% in patients with CKD stages 4 and 5, respectively [26]. With respect to safety, none of the patients in our G/P group showed treatment failure, and one patient discontinued the regimen due to AEs. G/P reportedly results in an SVR12 rate of 100% in genotype 2 HCV patients with severe renal impairment [26]. In this study, G/P also showed comparable SVR12 rate (90.9%) in patients with CKD stage 4–5. The G/P regimen as pangenotypic combination therapy is covered by medical insurance for patients with HCV genotype 2.

DCV + ASV showed an SVR12 of 83.3% in patients with HCV genotype 1b in this study. The treatment failure rate was 8.3% (2/24) and two patients discontinued the regimen due to AEs. DCV + ASV is no longer the recommended regimen because of the relatively longer treatment duration, and due to pre-existing and novel RAV of NS5A, resulting in a low SVR12 rate [27]. Therefore, G/P is a better treatment option than DCV + ASV in patients with severe renal impairment.

SOF is renally excreted and its accumulation results in renal dysfunction. The use of SOF in patients with CKD stage 4–5 (eGFR < 30 mL/min/1.73 m²) was not indicated on the label during the study period [28]. Therefore, we compared patients receiving an SOF-based regimen for CKD stage 3 to patients of CKD stage 1–2. Patients with CKD stage 3 showed a 95% SVR12, similar to the control group (96.1%). Moreover, none of them showed treatment failure, although two discontinued the treatment due to AEs.

Although DAAs are the first-line treatment for HCV, the choice of DAA regimen depends on HCV genotype, treatment history, eGFR, and hepatic fibrosis stage [29]. Additionally, careful review of the patient’s other medications is needed due to possible DDIs. When selecting DAAs based on renal function, the CKD stage is important. Although international guidelines (American Association for the Study of Liver Diseases) recommend the use of any DAA for CKD patients with an eGFR > 30 mL/min/1.73 m², the use of DAAs for patients with CKD 4–5 was not approved until 2016 [30]. The following regimens are recommended for genotype 1 patients with eGFR < 30 mL/min/1.73 m²: G/P, elbasvir/grazoprevir, ombitasvir/paritaprevir/ritonavir + dasabuvir, and SOF/LDV. For genotype 2, HCV patients, G/P and SOF/LDV are recommended.

The SVR12 rates in this study may be relatively lower than those reported in HCV patients with impaired renal function [25,31]. Not only G/P but also paritaprevir/ombitasvir/ritonavir + dasabuvir showed favorable SVR12 rates (100%) in genotype 1 HCV patients with severe renal impairment [32-34]. This inconsistency with our results can be explained as follows. First, there might be ambiguity regarding the baseline NS5A RAV for DCV + ASV. It is important to identify the baseline NSSA polymorphism before treatment with...
DCV + ASV. Although we assessed mutations at baseline in patients with CKD stage 4–5, indeterminate NS5A polymorphisms at baseline might have played a role in the virologic breakthrough. Second, managing tolerability and safety and increasing treatment adherence in difficult-to-treat patients are critical. Discontinuation of DAAs due to symptom-related nonadherence is an important cause of treatment failure. In addition, the number of patients with CKD stage 4–5 was small. The different numbers of patients hamper comparisons among studies.

Tolerability is also an important issue in difficult-to-treat patients. DAAs have a low frequency of AEs. The patients who discontinued antiviral medication in our study experienced AEs, including dizziness, dyspnea, and neutropenia. These AEs were not likely to be associated with DAAs. According to previous studies, common AEs of DAAs are fatigue, headache, pruritis, and nausea. These AEs do not affect the deterioration of renal or liver function [26]. In addition, monitoring of anemia is important because anemia is a common complication in patients with CKD. Anemia itself reportedly does not modulate the effectiveness of DAAs in hemodialysis, CKD, or kidney-transplant patients [34]. However, these patients had more comorbidities (e.g., HTN and DM) and a high risk of DDIs between DAAs and medications prescribed for underlying diseases, even with consideration of pharmaceutical reactions. Because interactions between metabolic pathways via the cytochrome P 3A4 enzyme and/or drug efflux pumps can alter the therapeutic effect of DAAs, thorough investigation of medications is needed before they are started [19,35]. Treatment failure or resistance to DAAs can be caused by DDIs resulting in subtherapeutic concentration [36]. Therefore, close monitoring and management of tolerability and DDIs is critical to the success of HCV therapy in CKD patients with CKD.

Our study had several strengths and limitations. First, it was the first Korean cohort study to analyze HCV-infected patients according to CKD stage. There are few data on the treatment effectiveness and safety of DAAs in patients with severe renal impairment in South Korea. Our results suggest that DAAs are effective and safe in HCV-infected patients with CKD. Although renal safety is an important issue for DAAs, especially in CKD patients, data thereon are lacking. Our results are in agreement with a report that DAA treatment does not affect renal function [37]. However, the number of patients in this study was small, and all patients had HCV genotype 1 or 2, so further studies are required to ascertain the safety profile of DAAs in CKD patients. Second, our findings show that G/P is the better option for Korean patients with chronic HCV and ESRD, although DCV + ASV may be suitable for genotype 1b HCV infection. However, other approved regimens (including paritaprevir, ritonavir, ombitasvir, dasabuvir, and elbasvir/grazoprevir) were not evaluated in this study because of the lack of patients with renal impairment. Third, we performed a comparative analysis with a control group. The substantial heterogeneity among studies might be attributable to variations in sample size and treatment regimens. Despite the small number of patients with severe CKD analyzed in this study, our results suggest a changing therapeutic landscape, with more DAAs becoming available for treating HCV in patients with chronic renal impairment.

In conclusion, DAAs show comparable SVR12 rates and safety profiles in CKD patients (eGFR < 60 mL/min/1.73 m²) with HCV compared with patients with an eGFR ≥ 60 mL/min/1.73 m² (91.8% vs. 96.3%, respectively). The effectiveness and safety of DAAs may be related to the treatment duration. Our findings highlight the importance of selecting an effective DAA regimen for CKD patients with HCV.

**KEY MESSAGE**

1. This is the first analysis of multiple direct acting antivirals (DAAs) in Korean patients with hepatitis C virus infection and renal impairment.
2. DAAs showed comparable sustained virologic response at week 12 after treatment among chronic kidney disease patients (estimated glomerular filtration rate [eGFR] < 60 mL/min/1.73 m²) with HCV compared with patients with an eGFR ≥ 60 mL/min/1.73 m² (91.8% vs. 96.3%, respectively). The effectiveness and safety of DAAs may be related to the treatment duration. Our findings highlight the importance of selecting an effective DAA regimen for CKD patients with HCV.
3. Most adverse events of DAAs were mild or moderate, suggesting comparable safety and tolerability profile of DAAs.
4. In this cohort, the majority of patients maintained renal function during and after DAA treatment.

**Conflict of interest**

No potential conflict of interest relevant to this article was reported.
REFERENCES

1. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347:975-982.

2. Hadziyannis SJ, Sette H Jr, Morgan TR, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004;140:346-355.

3. Fried MW. Side effects of therapy of hepatitis C and their management. Hepatology 2002;36(Suppl 1):S237-S244.

4. Kohli A, Shaffer A, Sherman A, Kotttilil S. Treatment of hepatitis C: a systematic review. JAMA 2014;312:631-640.

5. Wedemeyer H, Duberg AS, Buti M, et al. Strategies to manage hepatitis C virus (HCV) disease burden. J Viral Hepat 2014;21 Suppl 1:60-89.

6. Cotter TG, Paul S, Sandikci B, et al. Improved graft survival after liver transplantation for recipients with hepatitis C virus in the direct-acting antiviral era. Liver Transpl 2019;25:598-609.

7. Welzel TM, Petersen J, Herzer K, et al. Daclatasvir plus sofosbuvir, with or without ribavirin, achieved high sustained virological response rates in patients with HCV infection and advanced liver disease in a real-world cohort. Gut 2016;65:1861-1870.

8. Chen YC, Lin HY, Li CY, Lee MS, Su YC. A nationwide cohort study suggests that hepatitis C virus infection is associated with increased risk of chronic kidney disease. Kidney Int 2014;85:1200-1207.

9. Lee JJ, Lin MY, Chang JS, et al. Hepatitis C virus infection increases risk of developing end-stage renal disease using competing risk analysis. PLoS One 2014;9:e100790.

10. Kidney Disease: Improving Global Outcomes (KDIGO) Hepatitis C Work Group. KDIGO 2018 clinical practice guideline for the prevention, diagnosis, evaluation, and treatment of hepatitis C in chronic kidney disease. Kidney Int Suppl (2011) 2018;8:91-165.

11. Rogal SS, Yan P, Rimland D, et al. Incidence and progression of chronic kidney disease after hepatitis C seroconversion: results from ERCHIVES. Dig Dis Sci 2016;61:930-936.

12. Fabrizi F, Dixit V, Messa P. Impact of hepatitis C on survival in dialysis patients: a link with cardiovascular mortality? J Viral Hepat 2012;19:601-607.

13. Fabrizi F, Verdesca S, Messa P, Martin P. Hepatitis C virus infection increases the risk of developing chronic kidney disease: a systematic review and meta-analysis. Dig Dis Sci 2015;60:3801-3813.

14. Khedmat H, Amini M, Ghamar-Chehreh ME, Agah S. Hepatitis C virus infection in dialysis patients. Saudi J Kidney Dis Transpl 2014;25:1-8.

15. Ashkani-Esfahani S, Alavian SM, Salehi-Marzijarani M. Prevalence of hepatitis C virus infection among hemodialysis patients in the Middle-East: a systematic review and meta-analysis. World J Gastroenterol 2017;23:151-166.

16. Jadoul M, Bieber BA, Martin P, et al. Prevalence, incidence, and risk factors for hepatitis C virus infection in hemodialysis patients. Kidney Int 2019;95:939-947.

17. McGlynn EA, Adams JL, Kramer J, et al. Assessing the safety of direct-acting antiviral agents for hepatitis C. JAMA Netw Open 2019;2:e194765.

18. Mansour M, Hill L, Kerr J. Safety and effectiveness of direct-acting antivirals for treatment of hepatitis C virus in patients with solid organ transplantation. Transpl Infect Dis 2018;20:e12972.

19. Garrison KL, German P, Mogalain E, Mathias A. The drug-drug interaction potential of antiviral agents for the treatment of chronic hepatitis C infection. Drug Metab Dispos 2018;46:1212-1225.

20. Korean Association for the Study of the Liver. KASL clinical practice guidelines: management of hepatitis C. Clin Mol Hepatol 2016;22:76-139.

21. Forns X, Lee SS, Valdes J, et al. Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): a single-arm, open-label, multicentre phase 3 trial. Lancet Infect Dis 2017;17:1062-1068.

22. Kumada H, Watanabe T, Suzuki F, et al. Efficacy and safety of glecaprevir/pibrentasvir in HCV-infected Japanese patients with prior DAA experience, severe renal impairment, or genotype 3 infection. J Gastroenterol 2018;53:566-575.

23. Lin CW, Dutta S, Asatryan A, et al. Pharmacokinetics, safety, and tolerability of single and multiple doses of ABT-493: a first-in-human study. J Pharm Sci 2017;106:645-651.

24. Lin CW, Dutta S, Asatryan A, et al. Pharmacokinetics, safety, and tolerability following single and multiple doses of pibrentasvir in a first-in-human study. Clin Pharmacol Drug Dev 2018;7:44-52.

25. Gane E, Lawitz E, Pugatch D, et al. Glecaprevir and pibrentasvir in patients with chronic hepatitis C virus infection and severe renal impairment. N Engl J Med 2017;377:1448-1455.

26. Yap DY, Liu KS, Hsu YC, et al. Use of glecaprevir/pibrentasvir in patients with chronic hepatitis C virus infection and severe renal impairment. Clin Mol Hepatol 2020;26:554-561.
27. McPhee F, Suzuki Y, Toyota J, et al. High sustained virologic response to daclatasvir plus asunaprevir in elderly and cirrhotic patients with hepatitis C virus genotype 1b without baseline NS5A polymorphisms. Adv Ther 2015;32:637-649.

28. Yeon JE. Recent update of the 2017 Korean Association for the Study of the Liver (KASL) treatment guidelines of chronic hepatitis C: comparison of guidelines from other continents, 2017 AASLD/IDSA and 2016 EASL. Clin Mol Hepatol 2018;24:278-293.

29. Jadoul M, Martin P. Hepatitis C treatment in chronic kidney disease patients: the kidney disease improving global outcomes perspective. Blood Purif 2017;43:206-209.

30. AASLD/IDSA HCV Guidance Panel. Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. Hepatology 2015;62:932-954.

31. Roth D, Nelson DR, Bruchfeld A, et al. Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): a combination phase 3 study. Lancet 2015;386:1537-1545.

32. Iliescu EL, Mercan-Stanciu A, Toma L. Safety and efficacy of direct-acting antivirals for chronic hepatitis C in patients with chronic kidney disease. BMC Nephrol 2020;21:21.

33. Liu CH, Yang SS, Peng CY, et al. Glecaprevir/pibrentasvir for patients with chronic hepatitis C virus infection and severe renal impairment. J Viral Hepat 2020;27:568-575.

34. Elmowafy AY, Abbas MH, Denewar AA, et al. The effect of anemia on the efficacy and safety of treating chronic hepatitis C infection with direct-acting antivirals in patients with chronic kidney disease. Int Urol Nephrol 2021;53:749-761.

35. Shebley M, Liu J, Kavetskaia O, et al. Mechanisms and Predictions of drug-drug interactions of the hepatitis C Virus three direct-acting antiviral regimen: paritaprevir/ritonavir, ombitasvir, and dasabuvir. Drug Metab Dispos 2017;45:755-764.

36. Li PK, Bavanandan S, Mohamed R, et al. 2018 Kidney Disease: Improving Global Outcomes (KDIGO) hepatitis C in chronic kidney disease guideline implementation: Asia Summit Conference report. Kidney Int Rep 2020;5:1129-1138.

37. Driedger M, Galanakis C, Cooper C. Direct acting antiviral HCV treatment does not influence renal function. Medicine (Baltimore) 2020;99:e20436.